Forte Biosciences terminates patent license agreement with NIAID, effective April 2, 2022

Forte Biosciences, Inc.

Terminated Patent License Agreement with National Institute of Allergy and Infectious Diseases (NIAID).
Termination effective April 2, 2022.
Company will have no future payment obligations under the Agreement.

item 1.02

Forte Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-025772

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.